Associated Papers
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.
Kumondai M et al.
Journal of Personalized Medicine, 2021
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.
Nizamuddin S et al.
Pharmacogenomics and Personalized Medicine, 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.
Ohara M et al.
Plos One, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.
Villagra D et al.
Biomarkers in Medicine, 2011
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips.
Nakamoto K et al.
Pharmacogenetics and Genomics, 2007
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001